Twitter Facebook LinkedIn YouTube

BioMark Diagnostics (CSE: BUX) announced a Non-Brokered Private Placement

Video Platform Video Management Video Solutions Video Player

ioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively.

Additional Information:

Company: BioMark Diagnostics
Website: http://www.biomarkdiagnostics.com
Stock Symbol: CSE: BUX
Date Published: May 9, 2017
Transcript: Available

Video Transcript:

I’m Megan Edwards for Investmentpitch Media

BioMark Diagnostics (CSE:BUX) has announced a non-brokered private placement.

The company plans to raise gross proceeds of up to $500,000 through an offering of up to 5 million units priced at $0.10 per unit.

Each unit consists of 1 share and one-half a warrant, with each full warrant exercisable at $0.15 for a period of 24 months.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively.

The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

The size of the next-generation cancer diagnostic market is expected to grow from $1.8 billion in 2014 to $10 billion by 2019.

The shares are trading at $0.115.

For more information, please visit the company’s website, www.biomarkdiagnostics.com, contact Rashid Ahmed, President & CEO at 604-282-6567 or email info@biomarkdiagnostics.com.

I’m Megan Edwards for Investmentpitch Media